Patients Return on Engagement (ROE): A new framework to better captur... Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.
Digital Why pharma’s digital health tools miss the mark Explore the cultural, operational, and value-definition shifts required for digital health to deliver durable impact.
Digital Improving ROI on AI investments and data quality, with Dr Ja... Dr Jay Anders, chief medical officer for Medicomp Systems, discusses why he believes that the only way to solve AI ROI issues is to solve data quality
Market Access Capital efficient trials in a time of economic uncertainty In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, pharma and biotech companies should address not just whether a trial
R&D From promise to reality: Unlocking the true business potenti... The genomic medicine space has seen incredible success, but investors are overlooking it.
Digital Adopting AI platforms: A structured framework for thoughtful... The adoption of AI platforms, particularly in sectors such as drug discovery and healthcare, is a complex and critical process.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
